-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For a long time, the high sales expenses of listed pharmaceutical companies have become a chronic disease in the industry
.
This year is the first year of the "14th Five-Year Plan".
Anti-corruption in medicine is regarded as the most important work in the industry, and its intensity is constantly escalating
.
In August 2021, the National Health Commission issued a notice stating that from 2021 to 2024, special actions to rectify "red envelopes" and kickbacks will be carried out, and various institutions suspected of transferring benefits will be severely punished, transferred clues, and prohibited from entering the industry.
Continue to maintain a high-pressure crackdown on "red envelopes" and kickbacks; on November 16, the National Health Commission and other three departments jointly issued the "Notice on Printing and Distributing Nine Guidelines for the Clean Practice of Staff in Medical Institutions", aiming to standardize medical and health care Personnel practice behaviors guide the formation of a clean and upright industry environment to ensure the high-quality development of medical and health services
.
In addition, under the normalization of centralized procurement, the life of drug generation has become more difficult
.
Since the central procurement is directly negotiated by the state with pharmaceutical companies, the profit margins of pharmaceutical companies are constantly being squeezed, and the work of pharmacy is also facing severe challenges
.
Some analysts pointed out that in the long run, the accelerated promotion of the centralized procurement policy will not only benefit the benign and high-quality development of the pharmaceutical industry, it will also play a certain role in anti-corruption of the pharmaceutical industry by cutting off bribery channels from the source
.
But in the short term, pharmaceutical companies and pharmaceutical representatives are being forced to accelerate their transformation and upgrading
.
While pharmaceutical representatives are facing an increasingly difficult market development situation, they also need to deal with the wave of layoffs in pharmaceutical companies
.
The industry believes that, from the perspective of relevant policies and regulations, although the main crackdown is on the illegal activities of the medical representative, it has not denied all the work of the medical representative
.
The State Food and Drug Administration has also clarified the main tasks of medical representatives in the "Methods for the Administration of the Recordation of Medical Representatives" issued by the State Food and Drug Administration
.
But as a whole, affected by the squeeze of centralized procurement and the anti-corruption upgrade of pharmaceuticals, the survival space of 3 million pharmaceutical generations has become smaller and smaller.
In recent years, more and more news of pharmaceutical companies abolishing sales teams have come, and some of them are not lacking.
Large enterprises
.
With the continuous advancement of the medical reform policy, the transformation and upgrading of the pharmaceutical representative industry is imminent, and the pharmaceutical representatives who still choose to stay in the industry need to focus more on their own responsibilities, continue to improve the degree of specialization, and strive to do a good job in academic promotion.
.
In recent years, many pharmaceutical agents have begun to plan their transformation.
The main transformation directions include doctor brokers, medical device sales representatives, and the establishment of medical device operating companies
.
It is understood that as domestic doctors pay more and more attention to improving their technical level and service capabilities, doctor brokers have gradually emerged to help doctors complete IP packaging, multi-point practice docking, and legal risks such as medical disputes
.
According to the industry, relatively speaking, medical representatives have medical backgrounds, have long-term dealings with doctors, are familiar with doctors' working methods and business needs, and have extensive experience in academic activities and IP packaging
.
In the field of medical devices, under the high pressure of a series of policies such as the two-invoice system, the medical representative registration system, and strict control of the proportion of drugs, compared with the medical field, the environment for medical devices and consumables is relatively loose, which also attracts many drugs.
It is worth mentioning that the medical device market is also facing challenges such as centralized procurement and strict supervision.
It is recommended that the industry pay attention to industry development trends and make future plans after entering the industry, and increase the number of employees.
The competition is fierce.
Preparation
.
.
This year is the first year of the "14th Five-Year Plan".
Anti-corruption in medicine is regarded as the most important work in the industry, and its intensity is constantly escalating
.
In August 2021, the National Health Commission issued a notice stating that from 2021 to 2024, special actions to rectify "red envelopes" and kickbacks will be carried out, and various institutions suspected of transferring benefits will be severely punished, transferred clues, and prohibited from entering the industry.
Continue to maintain a high-pressure crackdown on "red envelopes" and kickbacks; on November 16, the National Health Commission and other three departments jointly issued the "Notice on Printing and Distributing Nine Guidelines for the Clean Practice of Staff in Medical Institutions", aiming to standardize medical and health care Personnel practice behaviors guide the formation of a clean and upright industry environment to ensure the high-quality development of medical and health services
.
In addition, under the normalization of centralized procurement, the life of drug generation has become more difficult
.
Since the central procurement is directly negotiated by the state with pharmaceutical companies, the profit margins of pharmaceutical companies are constantly being squeezed, and the work of pharmacy is also facing severe challenges
.
Some analysts pointed out that in the long run, the accelerated promotion of the centralized procurement policy will not only benefit the benign and high-quality development of the pharmaceutical industry, it will also play a certain role in anti-corruption of the pharmaceutical industry by cutting off bribery channels from the source
.
But in the short term, pharmaceutical companies and pharmaceutical representatives are being forced to accelerate their transformation and upgrading
.
While pharmaceutical representatives are facing an increasingly difficult market development situation, they also need to deal with the wave of layoffs in pharmaceutical companies
.
The industry believes that, from the perspective of relevant policies and regulations, although the main crackdown is on the illegal activities of the medical representative, it has not denied all the work of the medical representative
.
The State Food and Drug Administration has also clarified the main tasks of medical representatives in the "Methods for the Administration of the Recordation of Medical Representatives" issued by the State Food and Drug Administration
.
But as a whole, affected by the squeeze of centralized procurement and the anti-corruption upgrade of pharmaceuticals, the survival space of 3 million pharmaceutical generations has become smaller and smaller.
In recent years, more and more news of pharmaceutical companies abolishing sales teams have come, and some of them are not lacking.
Large enterprises
.
With the continuous advancement of the medical reform policy, the transformation and upgrading of the pharmaceutical representative industry is imminent, and the pharmaceutical representatives who still choose to stay in the industry need to focus more on their own responsibilities, continue to improve the degree of specialization, and strive to do a good job in academic promotion.
.
In recent years, many pharmaceutical agents have begun to plan their transformation.
The main transformation directions include doctor brokers, medical device sales representatives, and the establishment of medical device operating companies
.
It is understood that as domestic doctors pay more and more attention to improving their technical level and service capabilities, doctor brokers have gradually emerged to help doctors complete IP packaging, multi-point practice docking, and legal risks such as medical disputes
.
According to the industry, relatively speaking, medical representatives have medical backgrounds, have long-term dealings with doctors, are familiar with doctors' working methods and business needs, and have extensive experience in academic activities and IP packaging
.
In the field of medical devices, under the high pressure of a series of policies such as the two-invoice system, the medical representative registration system, and strict control of the proportion of drugs, compared with the medical field, the environment for medical devices and consumables is relatively loose, which also attracts many drugs.
It is worth mentioning that the medical device market is also facing challenges such as centralized procurement and strict supervision.
It is recommended that the industry pay attention to industry development trends and make future plans after entering the industry, and increase the number of employees.
The competition is fierce.
Preparation
.
